<DOC>
	<DOCNO>NCT02252146</DOCNO>
	<brief_summary>Recent report identify specific oncogenic mutation L265P MYD88 gene approximately 30 % patient activate B-cell ( ABC ) type Diffuse Large B Cell Lymphoma ( DLBCL ) . MYD88 initial adapter linker protein signal pathway Toll Like Receptors ( TLRs ) , include endosomal TLRs 7 , 8 , 9 , ligands nucleic acid . IMO-8400 oligonucleotide specifically design inhibit ligand activation TLRs 7,8 , 9 . Recent study indicate presence L265P mutation ligand activation TLRs result markedly increase signal subsequent increase cell activation , cell survival , cell proliferation . The scientific rationale assess use IMO-8400 treat patient DLBCL L265P mutation base laboratory observation IMO-8400 inhibits ligand-based activation cell mutation decrease survival proliferation cell population responsible propagation disease .</brief_summary>
	<brief_title>Dose Escalation Study Patients With Relapsed Refractory DLBCL MyD88 L265P Mutation</brief_title>
	<detailed_description>Eligible subject enrol assign one five dose cohort . Treatment administer subcutaneous injection progression intolerable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Patients must diagnosis Diffuse Large B Cell Lymphoma ( DLBCL ) nonGCB subtype , establish accord World Health Organization ( WHO ) criterion test MyD88 L265P mutation . In addition , key inclusion exclusion criterion list . 1 . Be least 18 year age 2 . Agree use contraception 1 . Is nurse pregnant 2 . DLBCL GCB subtype 3 . Has BMI &gt; 34.9 kg/m2 4 . Has positive test human immunodeficiency virus ( HIV1 2 ) hepatitis C virus ( HCV ) hepatitis B surface antigen ( HBsAg ) 5 . Receiving chronic systemic corticosteroid therapy &gt; 20 mg prednisone daily 6 . Being treated anticancer therapy ( approved investigational ) 7 . Has active infection require systemic antibiotic 8 . Has surgery require general anesthesia within 4 week start study 9 . Has heart failure Class III IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>MYD88 L265P</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse Large B Cell Lymphoma</keyword>
	<keyword>Idera</keyword>
	<keyword>IMO 8400</keyword>
</DOC>